Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States
HW Chesson, E Meites, DU Ekwueme… - Human vaccines & …, 2019 - Taylor & Francis
Estimates of medical care costs for cervical and other cancers associated with human
papillomavirus (HPV) are higher in studies published in recent years than in studies …
papillomavirus (HPV) are higher in studies published in recent years than in studies …
Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States
HW Chesson, DU Ekwueme, M Saraiya, M Watson… - Vaccine, 2012 - Elsevier
Estimates of the direct medical costs attributable to human papillomavirus (HPV) can help to
quantify the economic burden of HPV and to illustrate the potential benefits of HPV …
quantify the economic burden of HPV and to illustrate the potential benefits of HPV …
Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States
PA Clay, TD Thompson, LE Markowitz, DU Ekwueme… - Vaccine, 2023 - Elsevier
The annual direct medical cost attributable to human papillomavirus (HPV) in the United
States over the period 2004–2007 was estimated at $9.36 billion in 2012 (updated to 2020 …
States over the period 2004–2007 was estimated at $9.36 billion in 2012 (updated to 2020 …
Clinical and economic burden of HPV-related cancers in the US veteran population
K Saxena, RS Dawson, A Cyhaniuk… - Journal of Medical …, 2022 - Taylor & Francis
Background Human papillomavirus (HPV) is one of the most common sexually transmitted
infection in the United States and can lead to cervical, vulvovaginal, anal, penile, and …
infection in the United States and can lead to cervical, vulvovaginal, anal, penile, and …
Structural differences among cost–effectiveness models of human papillomavirus vaccines
RP Insinga, EJ Dasbach, EH Elbasha - Expert Review of Vaccines, 2008 - Taylor & Francis
In this article we compare previously published cost–effectiveness studies of human
papillomavirus (HPV) vaccines along a defined subset of key model structural assumptions …
papillomavirus (HPV) vaccines along a defined subset of key model structural assumptions …
Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas
Objective To estimate the average medical costs for vaginal and vulvar cancers in a
commercially insured population in the US and Texas. Methods 2011–2014 US MarketScan …
commercially insured population in the US and Texas. Methods 2011–2014 US MarketScan …
Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained
J Puig-Junoy, BG Lopez-Valcarcel - Preventive Medicine, 2009 - Elsevier
OBJECTIVE: We describe the heterogeneity of the estimates of the incremental cost per
quality-adjusted year of life (QALY) within and between cost-utility studies of the human …
quality-adjusted year of life (QALY) within and between cost-utility studies of the human …
Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?
IMCM de Kok, JDF Habbema, J van Rosmalen… - European journal of …, 2011 - Elsevier
Besides cervical cancer, the human papillomavirus (HPV) is found in other cancers and may
be preventable with HPV vaccination. However, these other cancers are often not accounted …
be preventable with HPV vaccination. However, these other cancers are often not accounted …
Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates
KJ Ong, M Checchi, L Burns, C Pavitt… - Sexually Transmitted …, 2019 - sti.bmj.com
Background Many economic evaluations of human papillomavirus vaccination should
ideally consider multiple disease outcomes, including anogenital warts, respiratory …
ideally consider multiple disease outcomes, including anogenital warts, respiratory …